Search

Your search keyword '"Kiso, Maki"' showing total 346 results

Search Constraints

Start Over You searched for: Author "Kiso, Maki" Remove constraint Author: "Kiso, Maki" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
346 results on '"Kiso, Maki"'

Search Results

3. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

4. Identification of SARS-CoV-2 Mpro inhibitors containing P1’ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

7. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents

10. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

11. Characterization of a new SARS-CoV-2 variant that emerged in Brazil

12. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters

15. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters

16. Neutrophil adhesion to vessel walls impairs pulmonary circulation in COVID-19 pathology

17. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

18. Genetic engineering employing MPB70 and its promoter enables efficient secretion and expression of foreign antigen in bacillus Calmette Guérin (BCG) Tokyo

20. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury

21. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets

22. Characterization of an EG.5.1 clinical isolate in vitro and in vivo

27. Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques

30. Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate

32. Characterization of a Feline Influenza A(H7N2) Virus

33. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo

34. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate

36. Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1

38. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

39. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB

40. Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB

41. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6

42. Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy

43. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates

45. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 clinical isolates

47. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.

48. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2

49. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters

50. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model

Catalog

Books, media, physical & digital resources